M
Marc André
Researcher at Université catholique de Louvain
Publications - 157
Citations - 6114
Marc André is an academic researcher from Université catholique de Louvain. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 31, co-authored 127 publications receiving 4881 citations. Previous affiliations of Marc André include The Catholic University of America.
Papers
More filters
Journal ArticleDOI
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hervé Tilly,M. Gomes da Silva,Umberto Vitolo,Andrew Jack,Michel Meignan,Armando López-Guillermo,Jan Walewski,Marc André,Peter Johnson,Michael Pfreundschuh,Marco Ladetto +10 more
TL;DR: This work presents the results of a double-blind, placebo-controlled study conducted at the University of Southampton over a two-week period in June and July of last year that demonstrated clear trends in prognosis for breast cancer in smokers and women with a history of smoking.
Journal ArticleDOI
Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients
Pierre W. Wijermans,Michael Lübbert,Gregor Verhoef,André Bosly,Christophe Ravoet,Marc André,Augustin Ferrant +6 more
TL;DR: It is confirmed that DAC therapy was effective in half of the studied patients with high-risk myelodysplastic syndrome and is especially active in the patients with the worst prognoses.
Journal ArticleDOI
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dennis A. Eichenauer,Andreas Engert,Marc André,Massimo Federico,Timothy M Illidge,Martin Hutchings,Marco Ladetto +6 more
TL;DR: The aim of this work is to provide a systematic review and meta-analysis of the literature on canine coronavirus infection and its role in mortality and morbidity and to help clarify the role of immune checkpoints in this disease.
Journal ArticleDOI
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Frederic Peyrade,Fabrice Jardin,Catherine Thieblemont,Antoine Thyss,Jean-François Emile,Sylvie Castaigne,Bertrand Coiffier,Corinne Haioun,Serge Bologna,Olivier Fitoussi,Gérard Lepeu,Christophe Fruchart,Dominique Bordessoule,Michel Blanc,Richard Delarue,Maud Janvier,Bruno Salles,Marc André,Marion Fournier,Philippe Gaulard,Hervé Tilly +20 more
TL;DR: In this article, the authors investigated the efficacy and safety of a decreased dose of CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisone) chemotherapy with a conventional dose of rituximab in elderly patients with diffuse large B-cell lymphoma.
Journal ArticleDOI
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma : Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc André,Theodore Girinsky,Massimo Federico,Oumedaly Reman,Catherine Fortpied,Manuel Gotti,Olivier Casasnovas,Pauline Brice,Richard W.M. van der Maazen,Alessandro Re,Veronique Edeline,Christophe Fermé,Gustaaf W. van Imhoff,Francesco Merli,Reda Bouabdallah,Catherine Sebban,Lena Specht,Aspasia Stamatoullas,Richard Delarue,Valeria Fiaccadori,Monica Bellei,Tiana Raveloarivahy,Annibale Versari,Martin Hutchings,Michel Meignan,John M. M. Raemaekers +25 more
TL;DR: In stage I and II HL, PET response after two cycles of ABVD allows for early treatment adaptation when ePET is positive, and switching to BEACOPPesc + INRT significantly improved 5-year PFS.